CN102145006A - Depression resistance application of panaxoside Ppt - Google Patents
Depression resistance application of panaxoside Ppt Download PDFInfo
- Publication number
- CN102145006A CN102145006A CN2010101075238A CN201010107523A CN102145006A CN 102145006 A CN102145006 A CN 102145006A CN 2010101075238 A CN2010101075238 A CN 2010101075238A CN 201010107523 A CN201010107523 A CN 201010107523A CN 102145006 A CN102145006 A CN 102145006A
- Authority
- CN
- China
- Prior art keywords
- ppt
- depression
- ginsenoside
- ginsenoside ppt
- panaxoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims abstract description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 11
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims abstract description 9
- 229930182494 ginsenoside Natural products 0.000 claims description 62
- 229940089161 ginsenoside Drugs 0.000 claims description 62
- 208000019022 Mood disease Diseases 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims description 5
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 206010025482 malaise Diseases 0.000 claims description 2
- 230000003340 mental effect Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 9
- 208000020401 Depressive disease Diseases 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 230000001430 anti-depressive effect Effects 0.000 description 16
- 239000000935 antidepressant agent Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 229940005513 antidepressants Drugs 0.000 description 12
- 241000208340 Araliaceae Species 0.000 description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 description 11
- 235000008434 ginseng Nutrition 0.000 description 11
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 11
- 229930182490 saponin Natural products 0.000 description 11
- 150000007949 saponins Chemical class 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 9
- 229960002748 norepinephrine Drugs 0.000 description 9
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 9
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 8
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 7
- 235000013402 health food Nutrition 0.000 description 7
- 229960002296 paroxetine Drugs 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 5
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
- 241000581650 Ivesia Species 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000037326 chronic stress Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- YFMPSMITLLBENU-UHFFFAOYSA-N 3,4-dihydroxybenzylamine Chemical compound NCC1=CC=C(O)C(O)=C1 YFMPSMITLLBENU-UHFFFAOYSA-N 0.000 description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001142635 Lema Species 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- -1 lactone glucoside Chemical class 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229930190770 brainoside Natural products 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910021397 glassy carbon Inorganic materials 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- WXKPPMQZRGORPB-UHFFFAOYSA-M sodium;2-hydroxypropane-1,2,3-tricarboxylic acid;acetate Chemical compound [Na+].CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O WXKPPMQZRGORPB-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Steroid Compounds (AREA)
Abstract
The invention discloses new application of panaxoside Ppt serving as metabolin of panaxoside Rg1 to the preparation of medicaments for preventing and treating depression. Experiments prove that the panaxoside Ppt has obvious curative effect, quick response and small toxic and side effects on the depression resistance, is a safe, efficient and stable anti-depression medicament, is suitable for industrial production and is easy to popularize. The panaxoside Ppt provides a new medicinal source for the prevention and treatment of depression and complications, impediment or diseases thereof.
Description
Technical field
The present invention relates to the medicine or the health food of a kind of prevention, alleviation and/or treatment affective disorders nervous system disease, particularly a kind of antidepressant drug or health food.
Background technology
Depression (depression) is the main type of affective disorders (mood disorders), be a kind of low with remarkable and persistent mental state be the syndrome of principal character.Depression is the able-bodied commonly encountered diseases of harm humans, frequently-occurring disease, is a global main mental disease.
Depression mainly shows as depressed, and interest lowers, pessimism, and retardation of thinking lacks initiative, and self-accusation is from crime, and diet, sleep are poor, worry oneself to suffer from various diseases, feel whole body many places discomfort, and suicidal thought and behavior can appear in severe patient.
Depression is the highest disease of psychiatric department homicide rate.The depression sickness rate is very high, among almost per 5 adults 1 patients with depression is just arranged, so it is called as the flu in the psychiatry.Depression has become second important diseases that causes serious burden in the global disease to the mankind at present, and to the misery that patient and family members thereof cause, the loss that society is caused is that other diseases is incomparable.The main cause that causes this situation is that society lacks correct understanding to depression, and prejudice makes the patient be reluctant that psychiatric department goes to a doctor.In China, only there is 5% patients with depression to accept treatment, a large amount of patients can not get diagnosis and treatment timely, and sb.'s illness took a turn for the worse, even the serious consequence of committing suiside occurs.On the other hand, because the common people lack the knowledge of relevant depression, the person thinks it is to be disgruntled by mistake to the depressive symptom occurring, can not give due understanding and emotion support, and the patient is caused bigger mental pressure, and the state of an illness is further worsened.
The seriousness day by day of depression fashion trend, the patient has caused the generally attention of countries in the world because of the decline of psychological diathesis due to the mental disorder with to the infringement of social function.The demand of antagonism down increases day by day in the world wide, and this quasi drugs world market sales volume every year is with 16.2% speed increment in recent years.The development of the control of depression and antidepressant new drug has become one of current international the world of medicine forward position hot research problem.
The Therapeutic Method of depression is a lot, as psychology treatment, sleep deprivation treatment, phototherapy and electric convulsive treatment etc., but at present still based on Drug therapy, is aided with the psychotherapy simultaneously.Present antidepressant main flow medicine has five big classes substantially: serotonin reuptake inhibitors (SSRIs) optionally, norepinephrine and specific serotonin reuptake inhibitors (NaSSA), tricyclic antidepressants counter inhibitor (TCAs), monoamine oxidase, MAO down (MAOIs) and serotonin and NRI (SNARI).These medicines all have untoward reaction in various degree, as drowsiness, blurred vision, hypertension, convulsions and hyposexuality etc., influencing it extensively promotes the use of, and these medicines are limit owing to himself defective, have that antidepressant spectrum is narrower, toxic and side effects is big, price is high, easily recur, be not suitable for problem such as the property nursed one's health treatment after the drug withdrawal, so had a strong impact on their clinical use.
Extract from traditional drugs in recent years that to have efficient antidepressant monomer medicine research increasing, become a kind of trend of international pharmacy industry exploitation antidepressant drug, for example German Herba Hyperici perforati (Herba Hyperici perforati) the extract hypericin of researching and developing, now listed the antidepressant main flow medicine of countries such as America and Europe in, but it is applicable to the slight and moderate depressive patients of treatment, the severe curative effect of depression is not shown, exist some potential safety hazards yet.
The inventor finds in the process of research ginsenoside Rg1 antidepressant function: the metabolite ginsenoside Ppt of ginsenoside Rg1 is easier to produce significant antidepressant effect by blood brain barrier, and efficacy stability, side effect is little, antidepressant drug and health food with its preparation have better quality controllability and universality, for serious depression definite curative effect are arranged also.
Ginsenoside Ppt is the metabolite of ginsenoside Rg1, and its molecular formula is C
30H
52O
4, molecular weight is 476.73, molecular structure is suc as formula shown in (I).
Modern pharmacological research shows that the metabolite ginsenoside Ppt of ginsenoside Rg1 has the purposes of anti-cognition, learning functionality obstacle, can be used for preparing the medicine and the health food that improve cognitive function and learning and memory function, but the application in preparation prevention and treatment depression medicine yet there are no report so far about ginsenoside Ppt.
Summary of the invention
Primary and foremost purpose of the present invention is the problem that exists at above-mentioned prior art, ginsenoside Ppt, the anti-affective disorders of ginsenoside Ppt compositions are provided, particularly antidepressant performance and effect, and ginsenoside Ppt or its pharmaceutically acceptable salt or its solvate are provided or contain the new pharmaceutical usage of compositions of effective dose ginsenoside Ppt, promptly in treatment, conditioning and the medicine of prevention depression, the new application in the health food.
For achieving the above object, one aspect of the present invention provides a kind of ginsenoside Ppt application in preparation prevention, alleviation and/or treatment affective disorders disease medicament or health product.
Wherein, described affective disorders disease is mainly depression.
Wherein, the metabolite ginsenoside Ppt of Radix Ginseng Saponin Rg1 of the present invention can prepare by commercially available or known method.
Wherein, described ginsenoside Ppt purity 〉=50%, be preferably 〉=80%, more preferably 〉=90%.
Wherein, the content of described ginsenoside Ppt 〉=50%, be preferably 〉=80%, more preferably 〉=90%.
Wherein, described medicine is formed by ginsenoside Ppt and pharmaceutically acceptable carrier or with other antidepressant chemical compound.
Particularly, pharmaceutically acceptable carrier is used for this purpose by sanitarian approval and usually as the non-active ingredient of medicament.The compilation of relevant pharmaceutically acceptable carrier can (Handbook of Pharmaceutical excipients, be edited by A.Wade and P.J.Weller by the 2nd edition in " handbook of pharmaceutical excipients "; American Pharmaceutical Association publishes, Washington and ThePharmaceutical Press, London, 1994) etc. find in the reference book.
Especially, described carrier comprises excipient, as starch, water etc.; Lubricant is as magnesium stearate etc.; Disintegrating agent is as microcrystalline Cellulose etc.; Filler is as lactose etc.; Binding agent is as pregelatinized Starch, dextrin etc.; Sweeting agent; Antioxidant; Antiseptic, correctives, spice etc.;
Wherein, described medicine is by through gastrointestinal administration and non-through the gastrointestinal administration administration.
Particularly, described non-through gastrointestinal administration approach selection drug administration by injection, respiratory tract administration, percutaneous drug delivery, mucosa delivery or cavity/canal drug administration.
Wherein, described medicine exists with forms such as tablet, capsule, pill, powder, granule, syrup, solution, injection, spray, aerosol, patches.
Wherein, non-through gastrointestinal administration medicament selection injection, spray, aerosol, patch etc.
Particularly, described through gastrointestinal administration preparation selection tablet, capsule, powder, granule, pill, solution or syrup etc.
The present invention provides the application of a kind of ginsenoside Ppt compositions in preparation prevention, alleviation and/or treatment affective disorders disease medicament or health product on the other hand.
Wherein said affective disorders disease is a depression.
Wherein, described ginsenoside Ppt compositions is selected the pharmaceutically solvate of the acceptable salt of ginsenoside Ppt, ginsenoside Ppt.
Wherein, described ginsenoside Ppt compositions can be that ginsenoside Ppt and other antidepressant chemical compound are formed preferably ginseng's Saponin Rg1 and/or ginsenoside Rh1.
Another aspect of the invention provides the application of pharmaceutical composition in preparation prevention, alleviation and/or treatment affective disorders disease medicament or health product of a kind of ginsenoside of comprising Ppt.
Wherein said affective disorders disease is a depression.
Further aspect of the present invention provides a kind of nutrient and health food that is used to prevent depression and/or alleviate depression disease symptom, it is characterized in that comprising ginsenoside Ppt.
The present invention also provides a kind of method for the treatment of depression, comprise to the experimenter and treat the ginsenoside Ppt of effective dose and/or the pharmaceutical composition of ginsenoside Ppt, its treatment effective dose is Radix Ginseng saponin P pt0.5～4mg/kgd, be preferably ginsenoside Ppt0.1～3mg/kgd, more preferably ginsenoside Ppt01.5～2mg/kgd.
Unless otherwise indicated, term used herein " treatment effective dose " is for needing to produce the amount of drug of useful effect; " treatment effective dose " can be adjusted and change, and finally determined by the medical worker, and its factor of considering comprises the character and the order of severity of the ordinary circumstance such as character, the receiver's of route of administration and preparation body weight, age and the disease for the treatment of.
Compared with prior art, the present invention has following obvious advantage:
1, the present invention has excavated metabolite ginsenoside Ppt or its pharmaceutically acceptable salt or the new medical value of its solvate of ginsenoside Rg1, use it for depression, and can be prepared into the medicine or the health food of prevention, conditioning and/or treatment depression.
2, the present invention studies have shown that ginsenoside Ppt is an antidepressant drug behind the receptor, by activating the cAMP-PKA path, promotes the phosphorylation of brain district CREB and the expression of rise BDNF, prevention and treatment depression.Experimental results show that ginsenoside Ppt can significantly shorten mouse tail suspension dead time and forced swimming dead time, the antidepressant effect of prompting Radix Ginseng saponin P pt may be better than the positive drug paroxetine.
3, Radix Ginseng saponin P pt of the present invention safety is good, suits to take for a long time, can be to the treatment of the depression property nursed one's health.
4, Radix Ginseng saponin P pt of the present invention both can adopt the medicine of single component preparation prevention and treatment depression, again can with the common prescription of other active component (for example with chemical compounds such as peoniflorin, lactone glucoside of Radix Paeoniae, glycyrrhizic acids), prepare the antidepressant compound medicine of many target spots.
Description of drawings
Accompanying drawing 1 is the influence of Radix Ginseng saponin P pt to PC12 neurocyte phosphorylation CREB
Accompanying drawing 2 is the influence of Radix Ginseng saponin P pt to PC12 neurocyte BDNF
The specific embodiment mode
Below in conjunction with specific embodiment, further set forth the present invention.Be not used in but these embodiment only limit to the present invention is described and limit the scope of the invention.The experimental technique of unreceipted concrete experiment condition in the following example, usually according to normal condition, or the condition of advising according to manufacturer.
Below further set forth the beneficial effect of medicine of the present invention by testing example, these test the routine pharmacodynamics test that has comprised medicine of the present invention.
Embodiment 1 ginsenoside Ppt is to the influence of mouse tail suspension experiment
1.1 experiment material
The ICR mice, male, body weight 18～20g provides quality certification numbering: SCXK (capital) 2007-0003 by dimension tonneau China zoopery center.
Ginsenoside Ppt (purity＞98%), Jilin Agriculture University China enlightening bio tech ltd provides;
Paroxetine, Sino-America Tianjin Shike Pharmaceutical Co., Ltd.'s (lot number: 08030078);
JZ type 300g tonotransducer (Gaobeidian City newly navigate accumulation equipment company limited);
Medlab bio signal acquisition processing system (Nanjing is easily beautiful)
1.2 experimental technique and result
Normal mouse is divided into 5 groups at random by body weight, 20 every group, i.e. model group, positive drug paroxetine (3.5mg/kg/d), ginsenoside Ppt height (10mg/kg/d), low (5mg/kg/d) dosage group.Each is organized all by 0.2ml/10g body weight gastric infusion, successive administration 2 days.
Used immobilization with adhesive tape on the line of 100g tonotransducer mice tail end (at distance tail point 2cm place) in the 2nd day after the administration 1h, make it be the state of hanging by the feet, head is tested 2 animals from the about 15cm of laboratory table at every turn simultaneously, separates with cardboard each other.Transducer is connected to Medlab bio signal acquisition processing system, and behind the adaptation 2min, the result within the record 4min is converted into the time (s) with motionless state.
Experimental data represents that with X ± SD experimental result is carried out variance analysis with SPSS11.5 statistical software (available from U.S. SPSS Inc.).Experimental result sees Table 1.
Table 1 ginsenoside Ppt is to the influence of mouse tail suspension dead time (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group
Experimental result shows:
Ginsenoside Ppt high and low dose group and positive drug paroxetine group all can significantly shorten the mouse tail suspension dead time (comparing P＜0.01 with model group), and prompting Radix Ginseng saponin P pt has good antidepressant function.
Embodiment 2, ginsenoside Ppt are to the influence of mice forced swimming experiment
2.1 experiment material
The ICR mice, male, body weight 18～20g provides quality certification numbering: SCXK (capital) 2007-0003 by dimension tonneau China zoopery center.
Ginsenoside Ppt (purity＞98%), Jilin Agriculture University China enlightening bio tech ltd provides;
Paroxetine, Sino-America Tianjin Shike Pharmaceutical Co., Ltd.'s (lot number: 08030078);
Thermometer, stopwatch, glass jar, Plato's digital camera head, notebook computer.
2.2 experimental technique
Normal mouse is divided into 5 groups at random by body weight, 20 every group, i.e. model group, positive drug paroxetine (3.5mg/kg/d), ginsenoside Ppt height (10mg/kg/d), low (5mg/kg/d) dosage group.Each is organized all by 0.2ml/10g body weight gastric infusion, successive administration 2 days, and the blank group is given deionized water.
After the 2nd day administration 1h,, observe 6min, adapt to 2min, the accumulative total dead time (s) in the 4min of record back the single water vat of putting into 23 ± 2 ℃ of high 20cm, diameter 18cm, depth of water 10cm, water temperature of mice.
Data are represented with x ± s, handle with the SPSS13.0 statistical software, and with One-Way ANOVA method, homogeneity of variance is checked with LSD and SNK.Experimental result sees Table 2.
Table 2 ginsenoside Ppt is to the influence of mice forced swimming dead time (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group
Experimental result shows: ginsenoside Ppt high and low dose group and positive drug paroxetine group all can obviously shorten the mice forced swimming dead time (comparing P＜0.01 with model group), show that ginsenoside Ppt has stronger antidepressant effect.
Embodiment 3 ginsenoside Ppt are to the influence of monoamine neurotransmitter in the chronic stress rat brain
3.1 experiment material
Be subjected to reagent: ginsenoside Ppt (purity＞98%), Jilin Agriculture University China enlightening bio tech ltd supplies;
Positive drug: fluoxetine Hydrochloride (Fluoxetine, Prozac fluoxetine), gift comes Suzhou pharmaceutical Co. Ltd, lot number: the accurate word J20030017 of traditional Chinese medicines, the rat consumption is 2.5mg/kg.
Norepinephrine (NE, Serva company); Dopamine (DA, Fluka company); 5-hydroxy tryptamine (5-HT, Sigma company); 3,4-dihydroxyphenyl acetic acid (DOPAC, Sigma company); 3,4-dihydroxy benzylamine (DHBA, Sigma company), di-n-butylamine (Shanghai chemical reagent factory), D-8 ion-pairing agent (Tianjin chemical reagent two factories), methanol (top grade is pure, the Beijing Chemical Plant), other reagent is homemade analytical pure.
The SD rat, male, body weight 220～240g.Provide quality certification numbering: 2007-0001 by dimension tonneau China zoopery center.
The Waters510 pump, M464 electrochemical detector DL-822 chromatographic work station (Dalian Chemistry and Physics Institute chromatograph center), MSE150 type ultrasonic disintegrator
3.2 experimental technique
3.2.1 grouping and administration
The SD rat, 24h gives 1% sucrose water after prohibiting the water non-fasting, measures the consumption in the 1h.Be divided into 6 groups at random according to the sucrose water consumption, 12 every group, i.e. normal control group, model group, positive drug fluoxetine Hydrochloride group (2.5mg/kg/d), ginsenoside Ppt height (8.6mg/kg/d), low (4.3mg/kg/d) dosage group.Modeling is gastric infusion simultaneously, once a day, and successive administration 21 days.Each group claims body weight weekly one time all by the administration of 1.0ml/100g body weight.
3.2.2 modeling
6/cage of normal control group is raised, and normal diet drinking-water is not given any stimulation.
Other five groups, 1/cage is raised, and accepts 21 days unpredictable stress stimulation, comprising: frozen water swimming, baking the affected part after applying some drugs, the folder tail, the moist raising put upside down round the clock, and water etc. is prohibited in fasting.Give a kind of stimulation every group of every day at random.
Every kind stress concrete operation method:
(1) frozen water swimming: animal is put into the bucket that fills 4 ℃ of cold water (frozen water mixing), depth of water 15cm, the toe of rat just can touch drum head, behind the 5min animal is taken out.
(2) baking the affected part after applying some drugs: oven temperature transfers to 45 ℃ and fixes, and animal is put into baking oven, behind the 5min animal is taken out.
(3) folder tail: rat is put into fixedly cage, expose tail, clamp apart from root of the tail portion 1cm place (it is not excessive to exert oneself, rat is sent wail get final product), lasting 1min with mosquito forceps.
(4) the moist raising: mornings 8 point, in mouse cage, add 200ml water, change to 8 of morning next day.
(5) put upside down round the clock: mornings 8 point, rat is put into dark case, 8 illuminations that turn on the light in evening are to the next day of 8 points early.
(6) fasting: 24h fracture.
(7) prohibit water: 24h cuts off the water supply.
3.2.3 sample preparation and detection
The animal sacrificed by decapitation is peeled off brain rapidly on ice, get prefrontal cortex, and the postposition of weighing is put into-70 ℃ of refrigerators and is saved to mensuration after organizing and using the liquid nitrogen quick freezing in the cryovial.
According to the weight of cerebral tissue, the 0.1mol/L that adds pre-cooling crosses chloric acid (including 0.3mM EDTA disodium and 0.5mM sodium sulfite), and 2 μ g/ml DHBA are mixed with 800 μ L, ultrasonic homogenate, and the centrifugal 10min of 11000rpm, supernatant are used for neurotransmitter and measure.
Adopt high-efficient liquid phase chromatogram-electrochemical detector system (HPLC-ECD) to measure, chromatographic condition is: chromatographic column is 4 * 150mm, Nova-pak Cl8,5 μ m (filling of chromatograph center, Dalian); Mobile phase is 50mM citric acid-sodium acetate buffer PH3.5 (including 1.0mM B-8 ion-pairing agent, 1.8mM di-n-butylamine, 0.3mM EDTA disodium, 4% methanol), flow velocity 1.0mL/min, and the vitreous carbon working electrode, detection cell voltage is+0.75V; 3,4-dihydroxy benzylamine DHBA is an internal standard substance, and each key component is carried out quantitatively with internal standard method in the sample.
Detect data and represent with x ± s, with SPSS 13.0 software processes, with One-Way ANOVA method, testing result sees Table 9,10.
Table 3 ginsenoside Ppt is to the influence of norepinephrine in the chronic stress rat brain (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group.
Table 4 ginsenoside Ppt is to the influence of serotonin in the chronic stress rat brain (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group.
Experimental data in the table 3,4 shows that successive administration obviously reduced (P＜0.05) with monoamine neurotransmitter norepinephrine, 5-hydroxy tryptamine content in the blank group comparison model group rat brain after 21 days; With monoamine neurotransmitter norepinephrine, 5-hydroxy tryptamine content in model group comparison ginsenoside Ppt high dose group and the positive drug fluoxetine Hydrochloride group rat brain obviously raise (P＜0.05).
Monoamine transmitters in the brain as insufficiency of function such as norepinephrine, 5-hydroxy tryptamine and dopamine, causes the depression morbidity.The reason that causes depression in the time of the reserpine blood pressure lowering is exactly because reserpine makes due to norepinephrine in the presynaptic membrane vesicle exhausts.This experimentation shows that 5-hydroxy tryptamine, noradrenaline cellulose content obviously reduce in the chronic stress rat brain, and ginsenoside Ppt can significantly improve the content of 5-hydroxy tryptamine, norepinephrine in the brain.Pointing out above effect may be one of the important mechanisms of the antidepressant effect of ginsenoside Ppt.
Embodiment 4 ginsenoside Ppt are to the influence experiment of PC12 cells phosphorylation CREB
4.1 experiment material
Cell culture: the PC12 cell is purchased the cell centre in Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, cultivates in the RPMI1640 culture medium, wherein adds volume fraction and be 10% horse serum and volume fraction and be 5% hyclone, in 37 ℃, and 5%CO
2Cultivate in the incubator.
Ginsenoside Ppt: provide purity＞98% (be configured to aqueous solution, be stored in 4 ℃ of refrigerators standby) by Jilin Agriculture University China enlightening bio tech ltd;
Monoclonal P-CREB Ser133 antibody (Cell Signaling Technology company);
The super quick luminescent solution of ECL is Beijing Puli's lema gene company product;
Electrophresis apparatus and electrophoresis tank (Liuyi Instruments Plant, Beijing); Electroporation (Bio-Rad); Microplate reader (EL311sBIO-TEK INSTRUMENTS Inc.); Milli Q plus ultra-pure water system (Millipore); Homogenizer (Polytran, Sweden); ECL detection system (Japanese fuji).
4.2 experimental technique:
4.2.1PC12 cell dosage regimen: the trophophase PC12 cell of taking the logarithm is with 10
7Density is inoculated in 6 orifice plates, and treating to give after adherent in 24 hours Radix Ginseng saponin P pt stimulates, extract after 48 hours cell protein prepare protein sample and be stored in-20 ℃ stand-by.
4.2.2 ginsenoside Ppt is to the influence of PC12 cell P-CREB: adopt western blot method that PC12 cell P-CREB level is detected.
4.3 experimental result:
Ginsenoside Ppt sees accompanying drawing 1 to the influence of PC12 neurocyte phosphorylation CREB.
Experimental result shows: ginsenoside Ppt can promote the expression of PC12 endocellular phosphorus acidify CREB.
Embodiment 5 ginsenoside Ppt are to the influence experiment of PC12 cell BDNF
5.1 experiment material
Cell culture: the PC12 cell is purchased the cell centre in Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, cultivates in the RPMI1640 culture medium, wherein adds volume fraction and be 10% horse serum and volume fraction and be 5% hyclone, in 37 ℃, and 5%CO
2Cultivate in the incubator.
Ginsenoside Ppt: provide purity＞98% (be configured to aqueous solution, be stored in 4 ℃ of refrigerators standby) by Jilin Agriculture University China enlightening bio tech ltd;
Polyclone BDNF antibody, β-Actin antibody and anti-rabbit igg two anti-(Santa Cruz Biotechnology company);
The super quick luminescent solution of ECL is Beijing Puli's lema gene company product;
Electrophresis apparatus and electrophoresis tank (Liuyi Instruments Plant, Beijing); Electroporation (Bio-Rad); Microplate reader (EL311sBIO-TEK INSTRUMENTS Inc.); Milli Q plus ultra-pure water system (Millipore); Homogenizer (Polytran, Sweden); ECL detection system (Japanese fuji).
5.2 experimental technique:
5.2.1PC12 cell dosage regimen: the trophophase PC12 cell of taking the logarithm is with 10
7Density is inoculated in 6 orifice plates, and treating to give after adherent in 24 hours Radix Ginseng saponin P pt stimulates, extract after 48 hours cell protein prepare protein sample and be stored in-20 ℃ stand-by.
5.2.2 ginsenoside Ppt is to the influence of PC12 cell BDNF: adopt western blot method that PC12 cell BDNF level is detected.
5.3 experimental result:
Ginsenoside Ppt sees accompanying drawing 2 to the influence of PC12 neurocyte BDNF.
Experimental result shows that ginsenoside Ppt can promote the expression of BDNF in the PC12 neurocyte.
Claims (5)
1. the metabolite ginsenoside Ppt of ginsenoside Rg1 is used for preventing, alleviate and/or treat the application of the medicine or the health product of affective disorders disease or symptom in preparation.
2. application according to claim 1 is characterized in that described mental sickness is a depression.
3. application according to claim 1 and 2 is characterized in that described medicine is made up of ginsenoside Ppt and pharmaceutically acceptable carrier.
4. application according to claim 1 and 2 is characterized in that described medicine exists with forms such as tablet, capsule, pill, powder, granule, syrup, solution, injection, spray, aerosol, patches.
5. the medicine or the health product of a prevention, alleviation and/or treatment depression disease is characterized in that comprising ginsenoside Ppt or the compositions of ginsenoside Ppt.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101075238A CN102145006A (en) | 2010-02-09 | 2010-02-09 | Depression resistance application of panaxoside Ppt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101075238A CN102145006A (en) | 2010-02-09 | 2010-02-09 | Depression resistance application of panaxoside Ppt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102145006A true CN102145006A (en) | 2011-08-10 |
Family
ID=44419608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101075238A Pending CN102145006A (en) | 2010-02-09 | 2010-02-09 | Depression resistance application of panaxoside Ppt |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102145006A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895256A (en) * | 2006-06-09 | 2007-01-17 | 上海中药创新研究中心 | Use of 20(S)-protopanoxadiol in preparation of antidepressant medicine |
| WO2008155998A1 (en) * | 2007-06-21 | 2008-12-24 | Nagase & Co., Ltd. | Antianxiety/antidepressant agent |
-
2010
- 2010-02-09 CN CN2010101075238A patent/CN102145006A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895256A (en) * | 2006-06-09 | 2007-01-17 | 上海中药创新研究中心 | Use of 20(S)-protopanoxadiol in preparation of antidepressant medicine |
| WO2008155998A1 (en) * | 2007-06-21 | 2008-12-24 | Nagase & Co., Ltd. | Antianxiety/antidepressant agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102038701B (en) | Anti-depression application of albiflorin | |
| CN105878322B (en) | It is a kind of to crystallize sunflower disk extract prepared by enzymatic isolation method and preparation method thereof | |
| CN105535048A (en) | Application of celery seed extract to preparation of medicine or health-care food for resisting to hyperuricemia and gout | |
| KR102227117B1 (en) | Use of 2,3,5-Substituted Thiophene Compound for Prevention, Improvement or Treatment of Breast Cancer | |
| CN103989677A (en) | Use of demethyleneberberine in preparation of blood sugar-reduction drug | |
| CN102014931B (en) | Use and preparation of paeoniflorin and the composition thereof | |
| CN101791314B (en) | Application of crocin in preparing hypnotic drug | |
| CN103919775A (en) | Application of 9-demethylberberine in preparation of hpyerglycemic drug | |
| CN105853382B (en) | A kind of Li Gelieting oral disintegrating tablet and preparation method thereof | |
| CN109350632A (en) | A kind of traditional Chinese medicine composition for antipyretic and analgesic | |
| CN101152173A (en) | Use of liquiritigenin in preparing medicament for treating neurodegenerative diseases | |
| CN119564671A (en) | Application of atractylodes lactone as β-glucuronidase inhibitor | |
| CN102145006A (en) | Depression resistance application of panaxoside Ppt | |
| CN102342949B (en) | Application of phlorhizin in preparation of drug for treating hyperuricemia | |
| CN101991577A (en) | Novel mental medicinal composition | |
| CN111265523A (en) | Application of berberine and ginsenoside composition in preparation of medicine for preventing and/or treating diabetes accompanied depression | |
| CN103816147A (en) | Novel pharmaceutical uses of garcinolic acid, neogambogic acid and composition of garcinolic acid and neogambogic acid | |
| CN101940585B (en) | Composition with orientin-2' -O-beta-L-galactoside as main component and application thereof | |
| AU2016256704B2 (en) | Pharmaceutical composition increasing cyclic AMP content and availability in vivo, and preparation method thereof | |
| CN106943408B (en) | Application of Tetramethyluric Acid in Prevention and Treatment of Diabetes | |
| CN117180331B (en) | External antipyretic traditional Chinese medicine composition and its preparation method, application and antipyretic gel patch | |
| CN104510854A (en) | Traditional Chinese medicinal composition for treating dysmenorrhea of women and application of traditional Chinese medicinal composition | |
| CN103880913A (en) | Compound with liver protection effect and application thereof | |
| CN103417786A (en) | Semen arecae prepareta extractive capable of promoting gastrointestinal motility and preparing method thereof | |
| CN102861045B (en) | Medicinal composition for treating neuropathic pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110810 |